

Pharmaceutical Services, 2 Franklin Street, Belfast BT2 8DQ
Telephone No. 028 95 36 0333

Medicine Supply Notification: Mometasone (Asmanex Twisthaler®)
200micrograms/dose dry powder and 400micrograms/dose dry powder inhalers

Tier 2 – medium impact

Date of issue: 20/10/2025

[Medicines Supply Tool – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice](#)

Summary

- Mometasone (Asmanex Twisthaler®) 200microgram/dose dry powder inhaler (60 dose) is being discontinued from late October 2025.
- Mometasone (Asmanex Twisthaler®) 200microgram/dose dry powder inhaler (30 dose) and 400micrograms/dose dry powder inhaler (30 dose and 60 dose) are being discontinued from late February 2026.
- Alternative corticosteroid inhalers remain available (see Supporting Information)

Actions Required

Prescribers should:

- not initiate new patients on Asmanex Twisthalers®;
- identify and review existing patients prescribed an Asmanex Twisthaler® and consider appropriateness of switching to another inhaled treatment in line with NICE asthma guidelines, [Overview | Asthma: diagnosis, monitoring and chronic asthma management \(BTS, NICE, SIGN\) | Guidance | NICE](#) (see Supporting Information); and
- ensure that the patient is not intolerant to any of the excipients in the new inhaler, is counselled on how to use the inhaler if judged suitable for use, on the dose to be administered, and to seek advice from their prescriber if asthma worsens.

If the above options are not considered appropriate, advice should be sought from specialists on management options.

Supporting information

Clinical Information

Mometasone dry powder inhalers are licensed for the regular treatment of asthma in adults and children 12 years of age and older

NICE asthma guidelines, [Recommendations | Asthma: diagnosis, monitoring and chronic asthma management \(BTS, NICE, SIGN\) | Guidance | NICE](#), updated in 2024 recommend that the initial management for newly diagnosed asthma in people aged 12 years and over should now be with either:

- Low-dose inhaled corticosteroid/formoterol combination to be taken as-needed (Anti-inflammatory reliever [AIR] therapy); or
- Low-dose maintenance and reliever (MART) therapy for patients with highly symptomatic asthma (e.g. regular nocturnal waking) or with a severe exacerbation, which can be stepped down to as-needed AIR therapy, if asthma is controlled.

The BNF, [Asthma, chronic | Treatment summaries | BNF | NICE](#), notes budesonide with formoterol is licensed for as-needed AIR therapy in mild asthma, and beclometasone with formoterol and budesonide with formoterol are licensed for MART.

Links to further information

- BNF Chronic asthma [Asthma, chronic | Treatment summaries | BNF | NICE](#)
- NICE guidelines [NG245]: Asthma [Overview | Asthma: diagnosis, monitoring and chronic asthma management \(BTS, NICE, SIGN\) | Guidance | NICE](#)
- SmPC Asmanex Twisthaler [Search Results - \(emc\)](#)
- SmPCs: Budesonide-Formoterol combination inhalers [Search Results - \(emc\)](#)
- SmPCs: Beclometasone- Formoterol combination inhalers [Search Results - \(emc\)](#)
- Right Breathe: Budesonide+ Formoterol inhalers [Vivaire 200micrograms/dose / 6micrograms/dose inhaler \(Zentiva Pharma UK Ltd\) 120 dose - RightBreathe](#)
- Right Breathe: Beclometasone + Formoterol inhalers [Vivaire 200micrograms/dose / 6micrograms/dose inhaler \(Zentiva Pharma UK Ltd\) 120 dose - RightBreathe](#)